keyword
MENU ▼
Read by QxMD icon Read
search

Dendritic cell vaccine

keyword
https://www.readbyqxmd.com/read/28717398/preclinical-evaluation-of-nf-%C3%AE%C2%BAb-triggered-dendritic-cells-expressing-the-viral-oncogenic-driver-of-merkel-cell-carcinoma-for-therapeutic-vaccination
#1
Kerstin F Gerer, Michael Erdmann, Sine R Hadrup, Rikke Lyngaa, Lena-Marie Martin, Reinhard E Voll, Beatrice Schuler-Thurner, Gerold Schuler, Niels Schaft, Stefanie Hoyer, Jan Dörrie
BACKGROUND: Merkel cell carcinoma (MCC) is a rare but very aggressive skin tumor that develops after integration of a truncated form of the large T-antigen (truncLT) of the Merkel cell polyomavirus (MCV) into the host's genome. Therapeutic vaccination with dendritic cells (DCs) loaded with tumor antigens is an active form of immunotherapy, which intends to direct the immune system towards tumors which express the respective vaccination antigens. METHODS: Cytokine-matured monocyte-derived DCs of healthy donors and MCC patients were electroporated with mRNA encoding the truncLT...
July 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/28716945/evaluating-optimal-therapy-robustness-by-virtual-expansion-of-a-sample-population-with-a-case-study-in-cancer-immunotherapy
#2
Syndi Barish, Michael F Ochs, Eduardo D Sontag, Jana L Gevertz
Cancer is a highly heterogeneous disease, exhibiting spatial and temporal variations that pose challenges for designing robust therapies. Here, we propose the VEPART (Virtual Expansion of Populations for Analyzing Robustness of Therapies) technique as a platform that integrates experimental data, mathematical modeling, and statistical analyses for identifying robust optimal treatment protocols. VEPART begins with time course experimental data for a sample population, and a mathematical model fit to aggregate data from that sample population...
July 17, 2017: Proceedings of the National Academy of Sciences of the United States of America
https://www.readbyqxmd.com/read/28716080/pretreatment-antigen-specific-immunity-and-regulation-association-with-subsequent-immune-response-to-anti-tumor-dna-vaccination
#3
Laura E Johnson, Brian M Olson, Douglas G McNeel
BACKGROUND: Immunotherapies have demonstrated clinical benefit for many types of cancers, however many patients do not respond, and treatment-related adverse effects can be severe. Hence many efforts are underway to identify treatment predictive biomarkers. We have reported the results of two phase I trials using a DNA vaccine encoding prostatic acid phosphatase (PAP) in patients with biochemically recurrent prostate cancer. In both trials, persistent PAP-specific Th1 immunity developed in some patients, and this was associated with favorable changes in serum PSA kinetics...
July 18, 2017: Journal for Immunotherapy of Cancer
https://www.readbyqxmd.com/read/28714919/overcoming-oncogenic-mediated-tumor-immunity-in-prostate-cancer
#4
REVIEW
Geoffrey Bryant, Lin Wang, David J Mulholland
Immunotherapy is being tested intensively in clinical trials for prostate cancer; it includes immune checkpoint inhibition, prostate specific antigen (PSA) vaccines and dendritic cell-based strategies. Despite increasing evidence for clinical responses, the consensus of multiple trials is that prostate cancers are poorly responsive to immunotherapy. Prostate cancer has a high degree of pathological and genetic heterogeneity compared to other cancer types, which may account for immunotherapeutic resistance. This hypothesis also implies that select types of prostate tumors may be differentially responsive to immune-based strategies and that the clinical stage, pathological grade and underlying genetic landscape may be important criteria in identifying tumors that respond to immune therapies...
July 17, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28714847/modulation-of-the-transcription-factor-nf-%C3%AE%C2%BAb-in-antigen-presenting-cells-by-bovine-respiratory-syncytial-virus-small-hydrophobic-protein
#5
Nicola Pollock, Geraldine Taylor, Fatoumatta Jobe, Efrain Guzman
Bovine respiratory syncytial virus (BRSV) is an important cause of respiratory disease in young cattle and is closely related to human RSV (HRSV), which causes severe respiratory disease in infants and the elderly. The RSV genome encodes a small hydrophobic (SH) protein with viroporin activity. Previous studies have shown that recombinant BRSV lacking the SH gene (rBRSVΔSH) is attenuated in the lungs, but not in the upper respiratory tract, of calves and mucosal vaccination with rBRSVΔSH induced long-lasting protective immunity...
July 17, 2017: Journal of General Virology
https://www.readbyqxmd.com/read/28714508/gold-glyconanoparticles-coupled-to-listeriolysin-o-91-99-peptide-serve-as-adjuvant-therapy-against-melanoma
#6
R Calderon-Gonzalez, H Terán-Navarro, I García, M Marradi, D Salcines-Cuevas, S Yañez-Diaz, A Solis-Angulo, E Frande-Cabanes, M C Fariñas, A Garcia-Castaño, J Gomez-Roman, S Penades, F Rivera, J Freire, C Álvarez-Domínguez
Dendritic cell-based (DC-based) vaccines are promising immunotherapies for cancer. However, several factors, such as the lack of efficient targeted delivery and the sources and types of DCs, have limited the efficacy of DCs and their clinical potential. We propose an alternative nanotechnology-based vaccine platform with antibacterial prophylactic abilities that uses gold glyconanoparticles coupled to listeriolysin O 91-99 peptide (GNP-LLO91-99), which acts as a novel adjuvant for cancer therapy. GNP-LLO91-99, when used to vaccinate mice, exhibited dual antitumour activities, namely, the inhibition of tumour migration and growth and adjuvant activity for recruiting and activating DCs, including those from melanoma patients...
July 17, 2017: Nanoscale
https://www.readbyqxmd.com/read/28714465/enhanced-anti-tumour-immunity-requires-the-interplay-between-resident-and-circulating-memory-cd8-t-cells
#7
Michel Enamorado, Salvador Iborra, Elena Priego, Francisco J Cueto, Juan A Quintana, Sarai Martínez-Cano, Ernesto Mejías-Pérez, Mariano Esteban, Ignacio Melero, Andrés Hidalgo, David Sancho
The goal of successful anti-tumoural immunity is the development of long-term protective immunity to prevent relapse. Infiltration of tumours with CD8(+) T cells with a resident memory (Trm) phenotype correlates with improved survival. However, the interplay of circulating CD8(+) T cells and Trm cells remains poorly explored in tumour immunity. Using different vaccination strategies that fine-tune the generation of Trm cells or circulating memory T cells, here we show that, while both subsets are sufficient for anti-tumour immunity, the presence of Trm cells improves anti-tumour efficacy...
July 17, 2017: Nature Communications
https://www.readbyqxmd.com/read/28713366/intratumoral-lentivector-mediated-tgf-%C3%AE-1-gene-downregulation-as-a-potent-strategy-for-enhancing-the-antitumor-effect-of-therapy-composed-of-cyclophosphamide-and-dendritic-cells
#8
Joanna Rossowska, Natalia Anger, Agnieszka Szczygieł, Jagoda Mierzejewska, Elżbieta Pajtasz-Piasecka
Vaccination with dendritic cells (DCs) stimulated with tumor antigens can induce specific cellular immune response that recognizes a high spectrum of tumor antigens. However, the ability of cancer cells to produce immunosuppressive factors drastically decreases the antitumor activity of DCs. The main purpose of the study was to improve the effectiveness of DC-based immunotherapy or chemoimmunotherapy composed of cyclophosphamide (CY) and DCs by application of lentivectors (LVs)-encoding short hairpin RNA specific for TGF-β1 (shTGFβ1 LVs)...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28713023/an-extended-mathematical-model-of-tumor-growth-and-its-interaction-with-the-immune-system-to-be-used-for-developing-an-optimized-immunotherapy-treatment-protocol
#9
Milad Qomlaqi, Fariba Bahrami, Maryam Ajami, Jamshid Hajati
BACKGROUND: chemotherapy is usually known as the main modality for cancer treatment. Nevertheless, most of chronic cancers could not be treated with chemotherapy alone. Immunotherapy is a new modality for cancer treatment that is effective for early stages of cancer and it has fewer side effects compared to chemotherapy, specifically for those types of cancer that are resistant to it. METHOD: This work presents an extended mathematical model to depict interactions between cancerous and adaptive immune system in mouse...
July 13, 2017: Mathematical Biosciences
https://www.readbyqxmd.com/read/28710434/modifying-dendritic-cell-activation-with-plasmonic-nano-vectors
#10
Kieng Bao Vang, Ingrid Safina, Emilie Darrigues, Dmitry Nedosekin, Zeid A Nima, Waqar Majeed, Fumiya Watanabe, Ganesh Kannarpady, Rajshekhar A Kore, Daniel Casciano, Vladimir P Zharov, Robert J Griffin, Ruud P M Dings, Alexandru S Biris
Dendritic cells (DCs) can acquire, process, and present antigens to T-cells to induce an immune response. For this reason, targeting cancer antigens to DCs in order to cause an immune response against cancer is an emerging area of nanomedicine that has the potential to redefine the way certain cancers are treated. The use of plasmonically active silver-coated gold nanorods (henceforth referred to as plasmonic nano vectors (PNVs)) as potential carriers for DC tumor vaccines has not been presented before. Effective carriers must be able to be phagocytized by DCs, present low toxicity, and induce the maturation of DCs-an early indication of an immune response...
July 14, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28710250/near-infrared-1064-nm-laser-modulates-migratory-dendritic-cells-to-augment-the-immune-response-to-intradermal-influenza-vaccine
#11
Kaitlyn Morse, Yoshifumi Kimizuka, Megan P K Chan, Mai Shibata, Yusuke Shimaoka, Shu Takeuchi, Benjamin Forbes, Christopher Nirschl, Binghao Li, Yang Zeng, Roderick T Bronson, Wataru Katagiri, Ayako Shigeta, Ruxandra F Sîrbulescu, Huabiao Chen, Rhea Y Y Tan, Kosuke Tsukada, Timothy Brauns, Jeffrey Gelfand, Ann Sluder, Joseph J Locascio, Mark C Poznansky, Niroshana Anandasabapathy, Satoshi Kashiwagi
Brief exposure of skin to near-infrared (NIR) laser light has been shown to augment the immune response to intradermal vaccination and thus act as an immunologic adjuvant. Although evidence indicates that the NIR laser adjuvant has the capacity to activate innate subsets including dendritic cells (DCs) in skin as conventional adjuvants do, the precise immunological mechanism by which the NIR laser adjuvant acts is largely unknown. In this study we sought to identify the cellular target of the NIR laser adjuvant by using an established mouse model of intradermal influenza vaccination and examining the alteration of responses resulting from genetic ablation of specific DC populations...
July 14, 2017: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/28704679/ph-sensitive-polymer-modified-liposome-based-immunity-inducing-system-effects-of-inclusion-of-cationic-lipid-and-cpg-dna
#12
Yuta Yoshizaki, Eiji Yuba, Naoki Sakaguchi, Kazunori Koiwai, Atsushi Harada, Kenji Kono
Efficient vaccine carriers for cancer immunotherapy require two functions: antigen delivery to dendritic cells (DCs) and the activation of DCs, a so-called adjuvant effect. We previously reported antigen delivery system using liposomes modified with pH-sensitive polymers, such as 3-methylglutarylated hyperbranched poly(glycidol) (MGlu-HPG), for the induction of antigen-specific immune responses. We reported that inclusion of cationic lipids to MGlu-HPG-modified liposomes activates DCs and enhances antitumor effects...
July 3, 2017: Biomaterials
https://www.readbyqxmd.com/read/28701761/antigen-specific-immunotherapies-in-rheumatic-diseases
#13
REVIEW
Judit Pozsgay, Zoltán Szekanecz, Gabriella Sármay
The main goal of antigen-specific immunotherapy (ASI) in autoimmune and rheumatic diseases is to reprogramme or remove autoreactive cells and/or induce immune tolerance to self-antigens. Current therapies in these diseases either treat symptoms or slow down disease progression but are not yet curative or preventative - disease-specific treatments are urgently needed. In contrast to the nonspecific treatments in current use that induce generalized immune suppression, which is associated with several adverse effects including increased risk of infections, ASIs target a restricted subset of B cells or T cells, and thus do not compromise systemic immunity and host defence...
July 13, 2017: Nature Reviews. Rheumatology
https://www.readbyqxmd.com/read/28700341/survival-of-metastatic-melanoma-patients-after-dendritic-cell-vaccination-correlates-with-expression-of-leukocyte-phosphatidylethanolamine-binding-protein-1-raf-kinase-inhibitory-protein
#14
Sonja I Buschow, Matteo Ramazzotti, Inge M J Reinieren-Beeren, Lucie M Heinzerling, Harm Westdorp, Irene Stefanini, Luca Beltrame, Stanleyson V Hato, Eva Ellebaek, Stefanie Gross, Van Anh Nguyen, Georg Weinlich, Jiannis Ragoussis, Dilair Baban, Beatrice Schuler-Thurner, Inge M Svane, Nikolaus Romani, Jonathan M Austyn, I Jolanda M De Vries, Gerold Schuler, Duccio Cavalieri, Carl G Figdor
Immunotherapy for metastatic melanoma offers great promise but, to date, only a subset of patients have responded. There is an urgent need to identify ways of allocating patients to the most beneficial therapy, to increase survival and decrease therapy-associated morbidity and costs. Blood-based biomarkers are of particular interest because of their straightforward implementation in routine clinical care. We sought to identify markers for dendritic cell (DC) vaccine-based immunotherapy against metastatic melanoma through gene expression analysis of peripheral blood mononuclear cells...
June 27, 2017: Oncotarget
https://www.readbyqxmd.com/read/28687661/a-systems-vaccinology-approach-reveals-temporal-transcriptomic-changes-of-immune-responses-to-the-yellow-fever-17d-vaccine
#15
Jue Hou, Shuhui Wang, Manxue Jia, Dan Li, Ying Liu, Zhengpeng Li, Hong Zhu, Huifang Xu, Meiping Sun, Li Lu, Zhinan Zhou, Hong Peng, Qichen Zhang, Shihong Fu, Guodong Liang, Lena Yao, Xuesong Yu, Lindsay N Carpp, Yunda Huang, Julie McElrath, Steve Self, Yiming Shao
In this study, we used a systems vaccinology approach to identify temporal changes in immune response signatures to the yellow fever (YF)-17D vaccine, with the aim of comprehensively characterizing immune responses associated with protective immunity. We conducted a cohort study in which 21 healthy subjects in China were administered one dose of the YF-17D vaccine; PBMCs were collected at 0 h and then at 4 h and days 1, 2, 3, 5, 7, 14, 28, 84, and 168 postvaccination, and analyzed by transcriptional profiling and immunological assays...
July 7, 2017: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/28686452/immunostimulatory-properties-of-lipid-modified-cpg-oligonucleotides
#16
Chunsong Yu, Myunggi An, Meng Li, Haipeng Liu
Innate immune responses recognizing pathogen associated molecular patterns play important roles in adaptive immunity. As such, ligands which mimic the conserved products of microbial and activate innate immunity are widely used as adjuvants for vaccines. Synthetic single strand oligodeoxynucleotides (ODNs) containing unmethylated cytosine-guanine (CpG) motifs which bind Toll-like receptor 9 (TLR9) are powerful molecular adjuvants, potentiating both humoral and cellular responses. However, CpG ODN's in vitro potency has not been translated to in vivo settings primarily due to issues associated with delivery and toxicity...
July 7, 2017: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/28680753/efficacy-of-vaccination-with-tumor-exosome-loaded-dendritic-cells-combined-with-cytotoxic-drug-treatment-in-pancreatic-cancer
#17
Li Xiao, Ulrike Erb, Kun Zhao, Thilo Hackert, Margot Zöller
Pancreatic cancer (PaCa) has a dismal prognosis and adjuvant immunotherapy frequently is of low efficacy due to immunosuppressive features of PaCa and PaCa-stroma. We here explored, whether the efficacy of vaccination with tumor-exosome (TEX)-loaded dendritic cells (DC) can be improved by combining with drugs affecting myeloid-derived suppressor cells (MDSC). Experiments were performed with the UNKC6141 PaCa line. UNKC6141 TEX-loaded DC were weekly intravenously injected, mice additionally receiving Gemcitabine (GEM) and/or ATRA and/or Sunitinib (Sun)...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28680744/intratumoral-delivery-of-tumor-antigen-loaded-dc-and-tumor-primed-cd4-t-cells-combined-with-agonist-%C3%AE-gitr-mab-promotes-durable-cd8-t-cell-dependent-antitumor-immunity
#18
Zuqiang Liu, Xingxing Hao, Yi Zhang, Jiying Zhang, Cara D Carey, Louis D Falo, Walter J Storkus, Zhaoyang You
The progressive tumor microenvironment (TME) coordinately supports tumor cell expansion and metastasis, while it antagonizes the survival and (poly-)functionality of antitumor T effector cells. There remains a clear need to develop novel therapeutic strategies that can transform the TME into a pro-inflammatory niche that recruits and sustains protective immune cell populations. While intravenous treatment with tumor-primed CD4(+) T cells combined with intraperitoneal delivery of agonist anti-glucocorticoid-induced TNF receptor (α-GITR) mAb results in objective antitumor responses in murine early stage disease models, this approach is ineffective against more advanced tumors...
2017: Oncoimmunology
https://www.readbyqxmd.com/read/28680376/dendritic-cell-dysfunction-in-patients-with-end-stage-renal-disease
#19
REVIEW
Ji Ung Kim, Miyeon Kim, Sinae Kim, Tam Thanh Nguyen, Eunhye Kim, Siyoung Lee, Soohyun Kim, Hyunwoo Kim
End-stage renal disease (ESRD) with immune disorder involves complex interactions between the innate and adaptive immune responses. ESRD is associated with various alterations in immune function such as a reduction in polymorphonuclear leukocyte bactericidal activity, a suppression of lymphocyte proliferative response to stimuli, and a malfunction of cell-mediated immunity at the molecular level. ESRD also increases patients' propensity for infections and malignancies as well as causing a diminished response to vaccination...
June 2017: Immune Network
https://www.readbyqxmd.com/read/28675699/immunization-with-a-synthetic-human-muc1-glycopeptide-vaccine-against-tumor-associated-muc1-breaks-tolerance-in-human-muc1-transgenic-mice
#20
Horst Kunz, Natascha Stergiou, Markus Glaffig, Helmut Jonuleit, Edgar Schmitt
Breaking the tolerance is crucial for an effective tumor immunotherapy. We showed that vaccines containing tumor-associated human MUC1 glycopeptides induce strong humoral anti-tumor responses in mice. The question remained whether such vaccines work in humans, in systems where huMUC1 is a self-antigen. To clarify the question, mice transgenic in expressing huMUC1, mimicking the self-tolerant environment, and wild-type mice were vaccinated with a synthetic vaccine. This vaccine comprised STn and Tn antigens bound to a MUC1 tandem repeat peptide coupled to Tetanus Toxoid...
July 4, 2017: ChemMedChem
keyword
keyword
8564
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"